Abstract
Breast cancer is a fatal disease whose incidence is gradually increasing in most industrialized countries and in all ethnic groups. Primary prevention is the ultimate goal for the control of this disease. The knowledge that breast cancer risk is reduced by early full-term pregnancy and that additional pregnancies increase the rate of protection has provided novel tools for designing cancer prevention strategies. The protective effect of pregnancy has been experimentally reproduced in virgin rats by treatment with the placental hormone human chorionic gonadotropin (hCG). HCG prevents the initiation and inhibits the progression of chemically induced mammary carcinomas by inducing differentiation of the mammary gland, inhibiting cell proliferation, and increasing apoptosis. It also induces the synthesis of inhibin, a tumor suppressor factor, downregulates the level of expression of the estrogen receptor alpha (ER-α) by methylation of CpG islands, imprinting a permanent genomic signature that characterizes the refractory condition of the mammary gland to undergo malignant transformation. The genomic signature induced by hCG is identical to that induced by pregnancy and is specific for this hormone. Comparison of the mammary gland’s genomic profile of virgin Sprague-Dawley rats treated daily with hCG for 21 days with that of rats receiving 17β-estradiol (E2) and progesterone (Pg) (E2+ Pg) revealed that in hCG-treated rats 194 genes were significantly up-modulated (>2.5 log2-folds) (p<0.01) and commonly expressed, whereas these genes were not expressed in the E2+ Pg group. The genomic signature induced by hCG and pregnancy included activators or repressors of transcription genes, apoptosis, growth factors, cell division control, DNA repair, tumor suppressor, and cell-surface antigen genes. Our data indicate that hCG, like pregnancy, induces permanent genomic changes that are not reproduced by steroid hormones and in addition regulates gene expression through epigenetic mechanisms that are differentiation-dependent processes, leading us to conclude that hormonally induced differentiation offers enormous promise for the primary prevention of breast cancer.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Albini A, Pagliefi L, Orengo G, Carlene S, Aluigi M, De Maachi R, Matteucci C, Mantovani A, Carozzi S, Benelli R (1997) The B-core fragment of human chorionic gonadotropin inhibits growth of Kaposi’s sarcoma derived cells and a new immortalized Kaposi’s sarcoma cell line. AIDS 11:713–72
Alvarado ME, Alvarado NE, Russo J, Russo IH (1994) Human chorionic gonadotropin inhibits proliferation and induces expression of inhibin in human breast epithelial cells in vitro. In Vitro 30:4–8
Alvarado MV, Russo J, Russo IH (1993) Immunolocalization of inhibin in the mammary gland of rats treated with hCG J Histochem Cytochem 41:29–34
Apter D (1996) Hormonal events during female puberty in relation to breast cancer risk. Eur J Cancer Prev 5:476–482
Armstrong DK, Issacs JT, Ottaviano YL and Davidson NE (1992) Programmed cell death in an estrogenindependent human breast cancer cell line MDAMB-468. Cancer Res 52:3418–3424
Baum M (2002) The ATAC (Arimidex Tamoxifen Alone or in Combination) adjuvant breast cancer trial in post-menopausal patients: factors influencing the success of patient recruitment. Eur J Cancer 38:1984–1986
Blair A, Zahm SH, Silverman DT (1999) Occupational cancer among women: Research status and methodologic considerations. Am J Ind Med 36:6–17
Boice JD Jr, Preston D, Davis FG, Monson RR (1991) Frequent chest X-ray fluoroscopy and breast cancer incidence among tuberculosis patients in Massachusetts. Radiat Res 125:214–222
Boudrau N, Sympson CJ, Werb Z, Bissell MJ (1995) Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 267:891–893
Buttyan R, Olsson CA, Pintar J, Chang C, Bandyk Ng P, Sawczuk IS (1989) Induction of the TRPM2 gene in cells undergoing programmed cell death. Mol Cell Biol 9:3473–3481
Calaf G, Russo J (1993) Transformation of human breast epithelial cells by chemical carcinogens. Carcinogenesis 14:483–492
Chang J, Elledge RM (2001) Clinical management of women with genomic BRCA1 and BRCA2 mutations. Breast Cancer Res Treat 69:101–113
Chie WC, Hsieh C, Newcomb PA, Longnecker MP, Mittendorf R, Greenberg ER, Clapp RW, Burke KP, Titus-Ernstoff L, Trentham-Dietz A, MacMahon B (2000) Age at any full-term pregnancy and breast cancer risk. Am J Epidemiol 151:715–722
Clemons M, Loijens L (2000) Goss P Breast cancer risk following irradiation for Hodgkin’s disease. Cancer Treat Rev 26:291–302
Coe K (1998) Breast cancer in Hispanic women. Women and Cancer 1:38–43
Collaborative Group on Hormonal Factors in Breast Cancer (2002) Breast cancer and breastfeeding: Collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries including 50302 women with breast cancer and 96973 women without disease. Lancet 360:187–195
Cutuli B, Borel C, Dhermain F, Magrini SM, Wasserman TH, Bogart JA, Provencio M, de Lafontan B, de la Rochefordiere A, Cellai E, Graic Y, Kerbrat P, Alzieu C, Teissier E, Dilhuydy J, Mignotte H, Velten (2001) M Breast cancer occurred after treatment for Hodgkin’s disease: analysis of 133 cases. Radiother Oncol 59:247–255
De Waard F, Thijssen JH (2005) Hormonal aspects in the causation of human breast cancer: epidemiological hypotheses reviewed with special reference to nutritional status and first pregnancy. J Steroid Biochem Mol Biol 97:451–458
Dunn BK, McCaskill-Stevens W, Kramer B, Ford LG (2000) Chemoprevention of breast cancer: The NSABP’s breast cancer prevention trial. J Women’s Cancer 2:177–19
El-Deiry W, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein (1993) B WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825
Evan GI, Littlewood TD (1993) The role of c-myc in cell growth. Curr Opin Genet Dev 3:44–49
Ewertz M, Duffy SW, Adami HO, Kvale G, Lund E, Meirik O, Mellemgaard A, Soini I, Tulinius H (1990) Age at first birth parity and risk of breast cancer: a meta-analysis of 8 studies from the Nordic countries. Int J Cancer 46:597–603
Fernandes-Alnemri T, Litwack G, Alnemri ES (1995a) Mch2, a new member of the apoptotic ced-3/ice cysteine protease gene family. Cancer Res 55:2737–2742
Fernandes-Ainemri T, Takashi A, Armstrong R, Krebs J, Fritz L, Tommaselli KJ, Wang L, Yu Z, Croce C M, Saiveson G, Earnshaw W C, Litwack G, Alnemri ES (1995b) Mch3, a novel human apoptotic cysteine protease highly related to CPP32. Cancer Res 5:6045–6052
Forbes JF (1997) The incidence of breast cancer: the global burden public health considerations. Semin Oncol 41[Suppl 1]:S1-20–S1-35
Fraumeni JF Jr, Lloyd JW, Smith EM, Wagoner JK (1969) Cancer mortality among nuns: Role of marital status in etiology of neoplastic disease in women. J Natl Cancer Inst 2:455–468
Gail MH, Brinton LA, Byar DP, Corle DK, Breen SB, Schairer C, Mulvihill JJ (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886
Gaudette LA, Silberberger C, Altmayer CA, Gao RN (1996) Trends in breast cancer incidence and mortality. Health Reports 8:29–37
Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer Statistics 2001. CA Cancer J Clin 1:15–36
Harris CC (1996) Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88:1442–1455
Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, Frost MH, Grant CS, Donohue JH, Woods JE, McDonnell SK, Vockley CW, Deffenbaugh A, Couch FJ, Jenkins RB (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93:1633–1637
Harvey KJ Blomquist JFI, Ucker DS (1998) Commitment and effector phases of the physiological cell death pathway elucidated with respect to Bcl-2 caspase and cyclin-dependent kinase activities. Mol Cell Biol 18:2912–2922
Hoffmann D, Hoffmann I, El-Bayoumy K (2001) The less harmful cigarette: a controversial issue, a tribute to Ernst L Wynder. Chem Res Toxicol 14:767–790
Holmberg E, Holm LE, Lundell M, Mattsson A, Wallgren A, Karlsson P (2001) Excess breast cancer risk and the role of parity age at first childbirth and exposure to radiation in infancy. Br J Cancer 85:362–366
Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG, Edwards BK (2001) Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 93:824–842
Janov AJ, Tulecke M, O’Neill A, Lester S, Mauch PM, Harris J, Schnitt SJ, Shapiro (2001) CL Clinical and Pathologic Features of Breast Cancers in Women Treated for Hodgkin’s Disease: A Case-Control Study. Breast J 7:46–52
Jemal A, Thomas A, Murray T, Thun M (2002) Cancer Statistics 2002. CA Cancer J Clin 52:23–47
Jernstrom H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C, Weber BL, Horsman D, Rosen B, Foulkes WD, Friedman E, Gershoni-Baruch R, Ainsworth P, Daly M, Garber J, Olsson H, Sun P, Narod SA (2004) Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 96:1094–1098
Johnson M, Dimitrov D, Vojta.PJ, Barrett JC, Noda A, Pereira-Smith OM, Smith JR (1994) Evidence for a p53-independent pathway for upregulation of SDI/CIPI/WAFI/p21 RNA in human cells. Mol Carcinog 1:59–64
Kelsey JL, Horn-Ross PL (1993) Breast Cancer: Magnitude of the problem and descriptive epidemiology. Epidemiol Rev 15:7–16
Khurana KK, Loosmann A, Numann PJ, Khan SA (2000) Prophylactic mastectomy-pathologic findings in high-risk patients. Arch Pathol Lab Med 124:378–381
King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286:2251–2256
Kyprianou N, English HF, Davidson NE, Issacs JT (1991) Programmed cell death during regression of MCF-7 human breast cancer following estrogen ablation. Cancer Res 51:162–166
Lambe M, Hsieh CC, Chan HW, Ekbom A, Trichopoulos D and Adami H O (1996) Parity age at first and last birth and risk of breast cancer: A populationbased study in Sweden. Breast Cancer Res Treat 38:305–311
Lynch HT, Casey MJ (2001) Current status of prophylactic surgery for hereditary breast and gynecologic cancers. Curr Opin Obstet Gynecol 13:25–30
MacMahon B, Cole P, Lin TM et al (1970) Age at first birth and breast cancer risk. Bull World Health Organ 43:209–221
Mailo D, Russo J, Sheriff F, Hu YF, Tahin Q, Mihaila D, Balogh G, Russo IH (2002) Genomic signature induced by differentiation in the rat mammary gland. Proc Am Assoc Cancer Res 43:5368a
Matsumoto H, Yamane T (2000) Green tea and cancer prevention. J Womens Cancer 2:153–158
McGregor DH, Land CE, Choi K, Tokuoka S, Liu PI, Wakabayashi I, Beebe GW (1977) Breast cancer incidence among atomic bomb survivors Hiroshima and Nagasaki 1950–1989. J Natl Cancer Inst 59:799–811
Merlo GR, Cella N, Hynes N (1997) Apoptosis is accompanied by changes in Bcl-2 and Bax expression induced by loss of attachment and inhibited by specific extracellular matrix proteins in mammary epithelial cells. Cell Growth Differ 8:251–260
Mgbonyebi O P, Tahin Q, Russo J, Russo IH (1996) Serum levels of chorionic gonadotropin in treated female rats during the progression of DMBA-induced tumorigenesis. Proc Am Assoc Cancer Res 37:1564a
Mgbonyebi OP, Russo J, Russo IH (1997) Induction of reversible growth arrest of immortal and neoplastic human breast epithelial cells by human chorionic gonadotropin (hCG). Proc Am Assoc Cancer Res 38:294–295
Mirza AN, Mirza NQ, Vlastos G, Singletary SE (2002) Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 235:10–26
Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596–2606
Nandi S, Guzman RC, Yang J (1995) Hormones and mammary carcinogenesis in mice rats and humans: a unifying hypothesis. Proc Natl Acad Sci U S A 92:3650–3657
Narod S (2001) Prophylactic mastectomy in carriers of BRCA mutations. N Engl J Med 345:1498; author reply 1499–1500
Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356:1876–1881
Nix JT (1964) Study of the relationship of environmental factors to the type and frequency of cancer causing death in nuns 1963. Hosp Prog 45:71–74
Ramazzini B (1965) De virginum vestalium valetudine tuenda dissertatio (a dissertation on the care of the health of nuns). J Occup Med 7:516–520
Rao DN, Ganesh B, Desai PB (1994) Role of reproductive factors in breast cancer in a low-risk area: a case-control study. Br J Cancer 70:129–152
Riggs T (2001) Prophylactic mastectomy in carriers of BRCA mutations. N Engl J Med 345:1499–500
Robertson JF, Nicholson RI, Bundred NJ, Anderson E, Rayter Z, Dowsett M, Fox JN, Gee JM, Webster A, Wakeling AE, Morris C, Dixon M (2001) Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 61:6739–6746
Ronen D, Schwartz D, Teitz Y, Goldfinger N, Rotter V (1996) Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild type p-53 protein whereas differentiation of the cells is mediated by lower p53 levels. Cell Growth Differ 7:21–30
Russo IH, Russo J (1993) Chorionic gonadotropin: a tumoristatic and preventive agent in breast cancer in drug resistance in oncology In: Teicher BA (ed), Marcel Dekker, pp 537–560
Russo IH, Russo J (1994) Role of hCG and inhibin in breast cancer (review). Int J Oncol 4:297–306
Russo IH, Russo J (1996) Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect 104:938–967
Russo IH, Russo J (1998) Role of pregnancy and chorionic gonadotropin in breast cancer prevention. In: Birkhauser MH, Rozenbaum H (eds) Proc IV European Congress on Menopause. ESKA, Paris, pp 133–142
Russo IH, Koszalka M, Russo J (1990a) Effect of human chorionic gonadotropin on mammary gland differentiation and carcinogenesis. Carcinogenesis 11:1849–1855
Russo IH, Koszalka M, Russo J (1990b) Human chorionic gonadotropin and rat mammary cancer prevention. J Natl Cancer Inst 82:1286–1289
Russo IH, Koszalka M, Russo J (1991) Comparative study of the influence of pregnancy and hormonal treatment on mammary carcinogenesis. Br J Cancer 64:481–484
Russo J, Russo IH (1980a) Influence of differentiation and cell kinetics on the susceptibility of the mammary gland to carcinogenesis. Cancer Res 40:2677–2687
Russo J, Russo IH (1980b) Susceptibility of the mammary gland to carcinogenesis. II Pregnancy interruption as a risk factor in tumor incidence. Am J Pathol 100:497–512
Russo J, Russo IH (1993) Developmental pattern of the human breast and susceptibility to carcinogenesis. Eur J Cancer Prevent 2:85–100
Russo J, Russo IH (1994) Toward a physiological approach to breast cancer prevention. Cancer Epidemiol Biomarkers Prev 3:353–364
Russo J, Russo IH (2000) Human chorionic gonadotropin in breast cancer prevention In: Ethier SP (ed) Endocrine oncology. Humana Press, Totowa, NJ, pp 121–136
Russo J, Janssens J, Russo IH (2000) Recombinant human chorionic gonadotropin (r-hCG) significantly reduces primary tumor cell proliferation in patients with breast cancer. Breast Cancer Res Treat 64:161a
Russo J, Saby J, Isenberg W, Russo IH (1977) Pathogenesis of mammary carcinoma induced in rats by 7,12-dimethylbenz(a)anthracene. J Natl Cancer Inst 59:435–445
Russo J, Wilgus G, Russo IH (1979) Susceptibility of the mammary gland to carcinogenesis. I Differentiation of the mammary gland as determinant of tumor incidence and type of lesion. Am J Pathol 96:721–734
Russo J, Tay LK, Russo IH (1982) Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 2:5–73
Russo J, Rivera R, Russo IH (1992) Influence of age and parity on the development of the human breast. Breast Cancer Res Treat 23:211–218
Sakamuro D, Eviner V, Elliott KJ, Showe L, White E, Prendergast GC (1995) C-myc induces apoptosis in epithelial cells by both p-53 dependent and p53 independent mechanisms. Oncogene 11:2411–2418
Shivvers SA, Miller DS (1997) Preinvasive and invasive breast and cervical cancer prior to or during pregnancy. Clin Perinatol 24:369–389
Simboli-Campbell M, Narvaez CJ, Tenniswood M, Welsh (1996) JE 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 58:367–376
Sinha DK, Patzik JE, Dao TL (1983) Progression of rat mammary development with age and its relationship to carcinogenesis by a chemical carcinogen. Int J Cancer 31:321–327
Srivastava P, Russo J, Russo IH (1998) Chorionic gonadotropin inhibits rat mammary carcinogenesis through activation of programmed cell death. Carcinogenesis 18:1799–1808
Srivastava P, Russo J, Russo IH (1999) Inhibition of rat mammary tumorigenesis by human chorionic gonadotropin is associated with increased expression of inhibin. Mol Carcinog 26:10–19
Stoutjesdijk MJ, Barentsz JO (2001) Prophylactic mastectomy in carriers of BRCA mutations. N Engl J Med 345:1499, author reply 1499–1500
Strobel T, Swanson L, Korsmeyer S, Cannistra SA (1996) Bax enhances pacitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci U S A 93:14094–14099
Sun M (1984) Panel says Depo-Provera not proved safe. Science 226:950
Tahin Q, Mgbonyebi OP, Russo J, Russo IH (1996) Influence of hormonal changes induced by the placental hormone chorionic gonadotropin on the progression of mammary tumorigenesis. Proc Am Assoc Cancer Res 37:1622a
Tanner JM (1973) Trend towards earlier menarche in London, Oslo, Copenhagen, the Netherlands and Hungary. Nature 243:95–96
Tay LK, Russo J (1981a) 7,12-dimethylbenz [a] anthracene-induced DNA binding and repair synthesis in susceptible and non-susceptible mammary epithelial cells in culture. J Natl Cancer Inst 7:155–161
Tay LK, Russo J (1981b) Formation and removal of 7,12-dimethylbenz [a] anthracene-nucleic acid adducts in rat mammary epithelial cells with different susceptibility to carcinogenesis. Carcinogenesis 2:1327–1333
Tay LK, Russo J (1983) Metabolism of 7,12-dimethylbe nz(a)anthracene by rat mammary epithelial cells in culture. Carcinogenesis 4:733–738
Tewari M, Quan LT, O’Rourke A, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM (1995) Yama/CPP32, a mammalian homolog of CED-3, is a Crm A-inhibitable protease that cleaves the death substrate poly(ADP-Ribose) polymerase. Cell 81:801–809
Trapido EJ (1983) Age at first birth parity and breast cancer risk. Cancer 51:946–948
Tymchuk CN, Tessler SB, Barnard RJ (2000) Changes in sex hormone-binding globulin insulin and serum lipids in postmenopausal women on a low-fat high-fiber diet combined with exercise. Nutr Cancer 38:158–162
Vermeulen A, Dhnodt M, Their YK, Van Der Kerckhove D (1976) Plasma sex steroid and gonadotropin levels in control and silastic vaginal medroxyprogesterone acetate-impregnated ring cycles. Fertil Steril 27:773–779
Vessey MD, McPherson K, Roberts MM, Neil A, Jones L (1985) Fertility and the risk of breast cancer. Br J Cancer 52:625–628
Warmuth MA, Sutton LM, Winer EP (1997) A review of hereditary breast cancer: From screening to risk factor modification. Am J Med 102:407–415
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Russo, I.H., Russo, J. (2007). Primary Prevention of Breast Cancer by Hormone-Induced Differentiation. In: Senn, HJ., Kapp, U. (eds) Cancer Prevention. Recent Results in Cancer Research, vol 174. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-37696-5_11
Download citation
DOI: https://doi.org/10.1007/978-3-540-37696-5_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-37695-8
Online ISBN: 978-3-540-37696-5
eBook Packages: MedicineMedicine (R0)